StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM)

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note released on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

NASDAQ:PULM opened at $2.09 on Tuesday. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75. The stock has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $1.99. The stock has a market capitalization of $7.63 million, a price-to-earnings ratio of -0.88 and a beta of 0.99.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The company had revenue of $1.55 million during the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.